Factors that affect libido
Endogenous compounds
Libido is governed primarily by activity in the mesolimbic dopamine pathway (ventral tegmental area and nucleus accumbens). Consequently, dopamine and related trace amines (primarily phenethylamine) that modulate dopamine neurotransmission play a critical role in regulating libido.Other neurotransmitters, neuropeptides, and sex hormones that affect sex drive by modulating activity in or acting upon this pathway include:

Testosterone (directly correlated) – and other androgens
Estrogen (directly correlated) – and related female sex hormones
Progesterone (inversely correlated)
Oxytocin (directly correlated)
Serotonin (inversely correlated)
Norepinephrine (directly correlated)
Acetylcholine

Sex hormone levels and the menstrual cycle
A womans desire for sex is correlated to her menstrual cycle, with many women experiencing a heightened sexual desire in the several days immediately before ovulation, which is her peak fertility period, which normally occurs two days before and until two days after the ovulation. This cycle has been associated with changes in a womans testosterone levels during the menstrual cycle. According to Gabrielle Lichterman, testosterone levels have a direct impact on a womans interest in sex. According to her, testosterone levels rise gradually from about the 24th day of a womans menstrual cycle until ovulation on about the 14th day of the next cycle, and during this period the womans desire for sex increases consistently. The 13th day is generally the day with the highest testosterone levels. In the week following ovulation, the testosterone level is the lowest and as a result women will experience less interest in sex.Also, during the week following ovulation, progesterone levels increase, resulting in a woman experiencing difficulty achieving orgasm.
The effectiveness of ropeginterferon alfa-2b was assessed by looking at how many participants achieved complete hematological response, which meant that participants had a red blood cell volume of less than 45% without a recent phlebotomy, normal white cell counts and platelet counts, a normal spleen size, and no blood clots. Overall, 61% of participants had a complete hematological response. The U.S. Food and Drug Administration (FDA) granted the application for Ropeginterferon_alfa-2b orphan drug designation and granted the approval of Besremi to PharmaEssentia Corporation

References
External links
"Ropeginterferon alfa-2b". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT01193699 for "Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (PEGINVERA)" at ClinicalTrials.gov
Clinical trial number NCT02218047 for "AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)" at ClinicalTrials.gov